DOCSLIB.ORG

ABSTRACTID TITLE AUTHORS 113502 Effect of PGE Inhibition on Striatal Neuroinflammation in 6-OHDA Lesion Temitope Adu; Musa Maban

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ABSTRACTID TITLE AUTHORS 113502 Effect of PGE Inhibition on Striatal Neuroinflammation in 6-OHDA Lesion Temitope Adu; Musa Maban ABSTRACTID TITLE AUTHORS 113502 Effect of PGE inhibition on striatal neuroinflammation in 6-OHDA lesion Temitope Adu; Musa Mabandla 113510 Chronic Toluene Exposure, Hippocampus-dependent Spacial Memory Nino Pochkhidze; Nino Pochkhidze and Hippocampal Structure. Experimental Study 113518 Difference in temperature between home and experimental tanks Benjamin Tsang; Hayden Chow; Hifsa Zahid; Rida Ansari; Richard alters behavioral responses in zebrafish. Chi Yeung Lee; Robert Gerlai 113533 You must stop balancing before you can walk Romain Tisserand; Christopher Dakin; Machiel Van der Loos; Elizabeth Croft; Timothy Inglis; Jean-Sebastien Blouin 113537 Involvement of orexinergic receptors within the nucleus accumbens in Abbas Haghparast; Marjan Sahafzadeh; Zahra Farzinpour stress- and drug priming-induced reinstatement of morphine-seeking behaviors in the rats 113611 White Matter Tract Alterations in Drug-naive Parkinson's Disease Mahtab Mojtahed Zadeh; Farzaneh Ghazi Sherbaf; Mohammad Patients with Impulse Control Disorders Hadi Aarabi 113745 Trait impulsiveness is related to smaller post-commissural putamen Fernando Caravaggio; Eric Plitman; Jun Chung; Philip Gerretsen; volumes in males but not females Julia Kim; Yusuke Iwata; Mallar Chakravarty; Gary Remington; Ariel Graff-Guerrero 113757 ASSESSING COGNITIVE-MOTOR INTEGRATION IN MIDDLE-AGED Andrea Cavaliere; Diana Gorbet; Lauren Sergio ATHLETES: THE EFFECTS OF DEMENTIA RISK & CONCUSSION 113758 Neuregulin-1 fosters a pro-regenerative response by microglia and Ghazaleh Mohammadzadeh Shahriary; Hardeep Kataria; Arsalan regulatory T cells in demyelinating conditions Alizadeh; Thomas K. Santhosh; Soheila Karimi-Abdolrezaee 113767 electrophysiological and firing properties of layer 2/3 and layer 5 of Homeira Moradi; lihua wang; Taufik valiante; liang zhang; peter human tissue: in vitro study carlen 113770 Control of Neuroplasticity Effector Arc/Arg3.1 by Protein Lysine Jasmin Lalonde; Surya Reis; Sudhir Sivakumaran; Carl Holland; Acetylation Hendrik Wesseling; John Sauld; Begum Alural; Wen-Ning Zhao; Judith Steen; Stephen Haggarty 113935 Neural adaptations in Parkinson’s Disease for complex locomotion Trina Mitchell; Alexander Thiel; Oury Monchi; Caroline Paquette 114156 IGF-1 activates AMPK to bidirectionally regulate mitochondrial function Mohamad-Reza Aghanoori; Darrell Smith; Mohammad Golam in adult sensory neurons Sabbir; Paul Fernyhough 114693 Effect of chronic cannabidiol treatment on memory functions in Abbas haghparast methamphetamine-addicted rats 114731 Sex Differences in QEEG in teenagerss with conduct disorder and Ana Calzada-Reyes; Alfredo Alvarez-Amador psychopathic traits 114737 ALS like motor impairment in prion diseases Eden Teferedegn 114753 Effect of orexin receptor 1 blockade in the anterior cingulate and SARA KARIMI; ABBAS Haghparast; Gholam Ali Hamidi orbitofrontal cortex on cost and benefit decision-making 114801 The nucleus reuniens thalami coordinates slow oscillatory activity Brandon Hauer; Silvia Pagliardini; Clayton Dickson between the neocortex and hippocampus 114820 Involvement of D1-like dopaminergic receptors in the nucleus Amirhossein Pirasteh; Abbas Haghparast accumbens in modulation of formalin-induced orofacial pain 114824 Neuregulin-1: a novel regulator of immune response in traumatic spinal Arsalan Alizadeh; Kallivalappil Santhosh; Hardeep Kataria; cord injury Adelilah S. Gounni; Soheila Karimi-Abdolrezaee 114889 Electrophysiological Profile of Differentiating Human Spinal Cord Stem Kyle Malone; Ahmad Galuta; Shawn Hayley; Eve Tsai; Michael Cells Hildebrand 114965 Association between peripheral neuroinflammation and DATSCAN data Hossein Sanjari Moghaddam of the striatal nuclei in PD patients 114969 Uncovering the molecular pathways regulating dopaminergic neurons Caroline Lafrechoux; Martin Lévesque axon guidance through PlexinC1 115024 Exogenous administration of Spermidine prevented 3-nitropropionic Sumit Jamwal; Puneet Kumar acid induced striatal toxicity: Reduction in oxido-nitrosative stress and restoration of striatal neurotransmitters level 115084 A model of failed remyelination to examine the mechanisms by which Greg Duncan; Brett Hilton; Peggy Assinck; Oscar Seira; Philip Ly; remyelination protects axons Ryan Hirata; Akash Gupta; Mohammad Asadi-Lari; Catherine Pallen; Jason Plemel; Wolfram Tetzlaff 115112 Development of an opioid self-administration assay to study drug Gabriel Bosse; Randall Peterson seeking in zebrafish 115133 Real-time evaluation of BACE1 activity on APP C99 site through a novel Bruno Herculano; Zhe Wang; Weihong Song cell-based protein reporter 115144 BACE2 is a conditional beta-secretase for Alzheimer Disease Zhe Wang; Qin Xu; Fang Cai; Xi Liu; Weihong Song 115169 Resting astrocyte calcium bidirectionally regulates tonic brain blood Jordan Haidey; Grant Gordon flow 115175 A presenilin-1 mutation causes Alzheimer disease without affecting Shuting Zhang; Yili Wu; Tahereh Bozorgmehr; Zhe Wang; Notch signaling Weihong Song 115190 Does Hippocampal State Influence Memory? Zemina Meghji; Claire Scavuzzo; Brandon Hauer; Clayton Dickson 115191 Circadian Rhythm Alters Anxiolytic Effects of Ethanol on Zebrafish Rida Ansari; Amna Azhar; Benjamin Tsang; Robert Gerlai Behaviour 115233 Cholinergic neurotransmission in different subregions of the substantia Jasem Estakhr; Danya Abazari; Kaitlyn Frisby; J. Michael nigra differentially controls DA neuronal excitability and locomotion McIntosh; Raad Nashmi 115244 Inflammatory cytokines, klotho and DPP4 plasma levels in the patients Mohsen Sedighi Mournani; Tourandokht Baluchnejadmojarad; with Alzheimer's disease Mehrdad Roghani; Siamak Afshin Majd 115296 Identification of novel Schwann cell-derived factors regulating axonal Jeremy Toma; Scott Yuzwa; David Kaplan; Freda Miller growth through cell-cell communication modelling 115324 Protracted post-traumatic neuronal death in the developing Trevor Balena; Negah Rahmati; Yero Saponjian; Kevin Staley hippocampus 115331 Locomotor recovery following contusive spinal cord injury does not Sohrab Manesh; Greg Duncan; Brett Hilton; Peggy Assinck; Jie require oligodendrocyte remyelination Liu; Aaron Moulson; Jason Plemel; Wolfram Tetzlaff 115445 A role for brain pericytes in cerebrovascular regeneration after stroke Louis-Philippe Bernier; Jasmin Hefendehl; Coral-Ann Lewis; Wilder Scott; Lasse Dissing-Olesen; Fabio Rossi; Micheal Underhill; Brian MacVicar 115451 Piezo1 is a novel calcium entry pathway in astrocytes Leigh Wicki-Stordeur; Rebecca Ko; Brian MacVicar 115510 Astrocyte-derived ACBP/DBI activates the hypothalamic melanocortin Khalil Bouyakdan; Chloé Chrétien; Demetra Rodaros; Fabienne pathway to regulate feeding and energy homeostasis. Liénard; Érik Biron; Luc Pénicaud; Xavier Fioramonti 115525 Acute astrogliosis and behavioural deficits in rats following repeated Melissa Clarkson; Brian Christie; Patrick Nahirney; Katie Neale; mild traumatic brain injury Sara Taylor 115631 Local blockage of cannabinoid signalling attenuates the orexigenic Alexander Edwards; Lindsay Hyland; Melissa Chee; Alfonso effect of ghrelin when it is infused into the VTA Abizaid 115641 Combining Visual Feedback and Functional Electrical Stimulation to Slav Dimov; Christoph Guger; Rupert Ortner; Woosang Cho Improve Motor Functions of Stroke Patients with a Brain-Computer Interface System 115642 Combining vibro-tactile P300 and Motor Imagery Brain-Computer Slav Dimov; Christoph Guger; Rossella Spataro; Alexander Interface to assess and communicate with Locked-in Patients Heilinger; Woosang Cho; Rupert Ortner 115672 A Genetic Variant of Fatty Acid Amide Hydrolase Regulates the Georgia Balsevich; Gavin Petrie; Arashdeep Singh; Martin Sticht; Opposing Crosstalk between Leptin and Glucocorticoids in the Context Stephanie Borgland; Prasanth Chelikani; Matthew Hill of Feeding 115719 Single APP knock-in mouse model of Alzheimer's disease showed age Sean Lacoursiere; Valerie Lapointe; Takashi Saito; Takaomi dependent cognitive deficit, cholinergic and catecholamine dysfunction Saido; Bruce McNaughton; Robert Sutherland; Robert McDonald; Majid Mohajerani 115722 Genetic disruption of Adipose Triglyceride Lipase (ATGL) in mediobasal Romane Manceau; Khalil Bouyakdan; Alexandre Fisette; hypothalamic neurons induces overweight and metabolic disturbances. Demetra Rodaros; Grant Mitchell; Stephanie Fulton; Thierry Alquier 115724 Regeneration of Auditory Neurons by Reprogramming Endogenous Steven Meas; Teppei Noda; Koji Nishimura; Alain Dabdoub Spiral Ganglion Glial Cells 115727 The possibility of improving processing speed with 3D MOT training: Stela Musteata; Kaya Yoshida; Caroline Spaner; Olav Krigolson; enhance memory performance in seniors Brian Christie 115728 Extending the translational validity of the CHIMERA (Closed Head Asma Bashir; Sophie Stukas; Kurt McInnes; Zelalem Abebe; Igor Impact Model of Engineered Rotational Acceleration) platform: Tatarnikov; Wai Hang Cheng; Carlos Barron; Anna Wilkinson; defining the relationships between neurological, electrophysiological, Guilaine Boyce; Matthew Farrer; Peter Cripton; Cheryl biochemical and neuropathological outcomes Wellington 115729 Imposing Structure on Odor Representations During Learning in OFC Peter Wang; Cristian Boboila; Kristen Lawlor; Richard Axel and BLA 115730 Uncommonly unconscious commonalities between sleep and Rachel Ward-Flanagan; Alto Lo; Marissa Sobey; Clayton Dickson anesthesia 115732 An intermittent hypercaloric diet alters gut microbiota, prefrontal Amy Reichelt; Amy Loughman; Ashton Bernard; James
Load more

Recommended publications
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Copyrighted Material
    Index Note: page numbers in italics refer to figures; those in bold to tables or boxes. abacavir 686 tolerability 536–537 children and adolescents 461 acamprosate vascular dementia 549 haematological 798, 805–807 alcohol dependence 397, 397, 402–403 see also donepezil; galantamine; hepatic impairment 636 eating disorders 669 rivastigmine HIV infection 680 re‐starting after non‐adherence 795 acetylcysteine (N‐acetylcysteine) learning disability 700 ACE inhibitors see angiotensin‐converting autism spectrum disorders 505 medication adherence and 788, 790 enzyme inhibitors obsessive compulsive disorder 364 Naranjo probability scale 811, 812 acetaldehyde 753 refractory schizophrenia 163 older people 525 acetaminophen, in dementia 564, 571 acetyl‐L‐carnitine 159 psychiatric see psychiatric adverse effects acetylcholinesterase (AChE) 529 activated partial thromboplastin time 805 renal impairment 647 acetylcholinesterase (AChE) acute intoxication see intoxication, acute see also teratogenicity inhibitors 529–543, 530–531 acute kidney injury 647 affective disorders adverse effects 537–538, 539 acutely disturbed behaviour 54–64 caffeine consumption 762 Alzheimer’s disease 529–543, 544, 576 intoxication with street drugs 56, 450 non‐psychotropics causing 808, atrial fibrillation 720 rapid tranquillisation 54–59 809, 810 clinical guidelines 544, 551, 551 acute mania see mania, acute stupor 107, 108, 109 combination therapy 536 addictions 385–457 see also bipolar disorder; depression; delirium 675 S‐adenosyl‐l‐methionine 275 mania dosing 535 ADHD
    [Show full text]
  • Pridopidine for the Treatment of Motor Function in Patients with Huntington’S Disease (Mermaihd): a Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial
    Articles Pridopidine for the treatment of motor function in patients with Huntington’s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial Justo Garcia de Yebenes, Bernhard Landwehrmeyer, Ferdinando Squitieri, Ralf Reilmann, Anne Rosser, Roger A Barker, Carsten Saft, Markus K Magnet, Alastair Sword, Åsa Rembratt, Joakim Tedroff, for the MermaiHD study investigators Summary Background Huntington’s disease is a progressive neurodegenerative disorder, characterised by motor, cognitive, and Lancet Neurol 2011; 10: 1049–57 behavioural deficits. Pridopidine belongs to a new class of compounds known as dopaminergic stabilisers, and results Published Online from a small phase 2 study in patients with Huntington’s disease suggested that this drug might improve voluntary November 8, 2011 motor function. We aimed to assess further the effects of pridopidine in patients with Huntington’s disease. DOI:10.1016/S1474- 4422(11)70233-2 See Comment page 1036 Methods We undertook a 6 month, randomised, double-blind, placebo-controlled trial to assess the efficacy of pridopidine Department of Neurology, in the treatment of motor deficits in patients with Huntington’s disease. Our primary endpoint was change in the Hospital Ramón y Cajal, modified motor score (mMS; derived from the unified Huntington’s disease rating scale) at 26 weeks. We recruited CIBERNED, Madrid, Spain patients with Huntington’s disease from 32 European centres; patients were aged 30 years or older and had an mMS of (J G de Yebenes MD); 10 points or greater at baseline. Patients were randomly assigned (1:1:1) to receive placebo, 45 mg per day pridopidine, Department of Neurology, University of Ulm, Ulm, or 90 mg per day pridopidine by use of centralised computer-generated codes.
    [Show full text]
  • Etiology and Pathogenesis of Parkinson's Disease
    Phenomenology and classification of dystonia: A consensus update. Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, Hallett M, Jankovic J, Jinnah HA, Klein C, Lang AE, Mink JW, Teller JK. Update on Dystonia, Mov Disord 2013;28:863-73 • Dystonia is defined as a movement disorder characterized Chorea, and Tics by sustained or intermittent muscle contractions causing abnormal, often repetitive, movements, postures, or both. Joseph Jankovic, MD • Dystonic movements are typically patterned and twisting. Professor of Neurology, Distinguished Chair in Movement Disorders, • Dystonia is often initiated or worsened by voluntary action Director, Parkinson's Disease Center and Movement Disorders Clinic, and associated with overflow muscle activation. Department of Neurology, Baylor College of Medicine, Houston, Texas • Some forms of dystonia, such as blepharospasm and laryngeal dystonia, are not associated with postures, but are characterized by focal involuntary contractions that interfere with physiological opening or closing of the eyelids or the larynx. • Dystonia is classified along two axes: 1. Clinical characteristics, including age at onset, body distribution, temporal pattern and associated features (additional movement disorders or neurological features) 2. Etiology, which includes nervous system pathology and inheritance. The prevalence of primary dystonia: A systematic review and meta‐analysis Steeves et al. Mov Disord 2012;27:1789-96 Genetic Classification of Dystonias Genetic Classification of Dystonias Primary Dystonias
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Pridopidine in Huntington Disease Pridopidine Is Currently in Development for Huntington Disease (HD)
    Pridopidine in Huntington Disease Pridopidine is currently in development for Huntington disease (HD). Multiple clinical studies have been conducted providing important understanding about safety, mechanism of action, and efficacy. HD is a rare, inherited, chronically progressive and ultimately fatal brain disease. The disease typically starts between the ages of 30 to 50, and causes loss of physical, mental, and emotional abilities. Key symptoms of HD include: • Personality changes, mood swings, and depression (including increased suicidal ideation), • Forgetfulness and impaired judgment, • Unsteady gait and involuntary movements (chorea), and • Slurred speech, difficulty in swallowing, and significant weight loss Originally, pridopidine was thought to exert its effects by modifying dopamine signaling through dopamine receptors. Dopamine is a chemical (neurotransmitter) produced in the brain important for regulating movement. Therefore, prior trials with pridopidine in HD were designed to assess primarily the effect of pridopidine on motor symptoms (like slow and/or abnormal movements). The PRIDE-HD study was originally designed as a 26-week, phase 2, randomized, placebo- controlled clinical trial evaluating four different doses (between 45.0–112.5 mg twice a day) of pridopidine for the treatment of Huntington disease. The four different and increasing doses were planned because for dopamine modulators, higher doses were expected to be more efficacious. While the PRIDE-HD trial was ongoing, new research showed that the effect of pridopidine was not mediated by the dopamine receptor but rather via activation of the Sigma-1 receptor (S1R). The S1R is a protein expressed at high levels in the brain and in motor neurons of the spinal cord.
    [Show full text]
  • Comparative in Vivo Pharmacology of Dopidines a Novel Class of Compounds Discovered by Phenotypic Screening
    Comparative in vivo pharmacology of dopidines A novel class of compounds discovered by phenotypic screening Susanna Holm Waters Department of Pharmacology Institute of Neuroscience and Physiology Sahlgrenska Academy at University of Gothenburg Gothenburg 2015 Comparative in vivo pharmacology of dopidines © Susanna Holm Waters 2015 [email protected] ISBN 978-91-628-9501-3 (print) ISBN 978-91-628-9502-0 (pdf) http://hdl.handle.net/2077/39542 Printed in Gothenburg, Sweden 2015 Ineko AB Le doute n'est pas un état bien agréable, mais l'assurance est un état ridicule. Voltaire, letter, 1770 Reason is, and ought only to be the slave of the passions, and can never pretend to any other office than to serve and obey them. David Hume, A Treatise of Human Nature Comparative in vivo pharmacology of dopidines Susanna Holm Waters Department of Pharmacology, Institute of Neuroscience and Physiology Sahlgrenska Academy at University of Gothenburg Göteborg, Sweden ABSTRACT Dopidines are a novel class of dopamine (DA) modulating compounds, developed to provide improved treatment of a range of neurodegenerative and psychiatric disorders that are currently managed to a large extent with anti- dopaminergic medications. The overall aim of the present work was to investigate the in vivo pharmacology of dopidines, as compared to other classes of monoamine modulating compounds. A further aim was to explore the long term effects of antidopaminergic medication in Huntington’s disease (HD), a neurodegenerative disorder characterized by motor, behavioural, and cognitive symptoms. Data from REGISTRY, an observational study on patients with HD, were analysed by means of principal component analysis, bivariate regression, and multiple regression, to assess the potential impact of antidopaminergic medications on motor and functional outcomes.
    [Show full text]
  • April Through June 2014
    April through June 2014 Undeclared Drug Ingredient Found in MV5 Days: Updated Warnings—Current Drugs The FDA is advising consumers not to purchase or use MV5 Days, a product promoted and sold for sexual en- hancement. FDA laboratory analysis confirmed that MV5 Public Notification Regarding Male Sexual En- Days contains sildenafil, the active ingredient in the FDA hancement Products: The FDA is advising consumers approved prescription drug Viagra, used to treat ED. This not to purchase or use GoldReallas, Full Throttle On De- undeclared ingredient may interact with nitrates found in mand, 3 Hard Knights, Dick’s Hard Up, Eyeful, Liu Bian Li, some prescription drugs such as nitroglycerin and may products promoted and sold for sexual enhancement on lower blood pressure to dangerous levels. Men with diabe- various websites and in some retail stores. FDA laboratory tes, high blood pressure, high cholesterol, or heart disease analysis confirmed that these products contained the fol- often take nitrates. lowing undeclared drug ingredients: MV5 Days is a product promoted and sold for sexual en- • GoldReallas: sildenafil and thiosildenafil hancement on various websites and in some retail stores. • Full Throttle On Demand: propoxyphenyl sildenafil FDA is recommending that consumers do not purchase or • 3 Hard Knights: sildenafil and thiosildenafil use MV5 Days. (5/16/14) • Dick’s Hard Up: tadalafil • Eyeful: hydroxythiohomosildenafil Lunesta—Next Day Impairments: The FDA has noti- • Liu Bian Li: sildenafil fied health professionals and their medical care organiza- These undeclared ingredients may interact with nitrates tions of a new warning that the insomnia drug Lunesta found in some prescription drugs such as nitroglycerin and (eszopiclone) can cause next-day impairment of driving may lower blood pressure to dangerous levels.
    [Show full text]
  • Prokineticin 2 Signaling: Genetic Regulation and Preclinical Assessment in Rodent Models of Parkinsonism Jie Luo Iowa State University
    Iowa State University Capstones, Theses and Graduate Theses and Dissertations Dissertations 2018 Prokineticin 2 signaling: Genetic regulation and preclinical assessment in rodent models of Parkinsonism Jie Luo Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/etd Part of the Toxicology Commons Recommended Citation Luo, Jie, "Prokineticin 2 signaling: Genetic regulation and preclinical assessment in rodent models of Parkinsonism" (2018). Graduate Theses and Dissertations. 17254. https://lib.dr.iastate.edu/etd/17254 This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Prokineticin 2 signaling: Genetic regulation and preclinical assessment in rodent models of Parkinsonism by Jie Luo A dissertation submitted to the graduate faculty in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY Major: Toxicology Program of Study Committee: Anumantha Kanthasamy, Co-major Professor Arthi Kanthasamy, Co-major Professor Mark Ackermann Cathy Miller Thimmasettappa Thippeswamy The student author, whose presentation of the scholarship herein was approved by the program of study committee, is solely responsible for the content of this dissertation. The Graduate College will ensure this dissertation is globally accessible and will not permit alterations after a degree is conferred. Iowa State University Ames, Iowa 2018 Copyright © Jie Luo, 2018. All rights reserved. ii DEDICATION To God, my dear mother Leanne, and my girlfriend Haiyang iii TABLE OF CONTENTS Page ACKNOWLEDGMENTS .................................................................................................
    [Show full text]
  • (Propyl)Amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease S
    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2020/05/01/jpet.119.264226.DC1 1521-0103/374/1/113–125$35.00 https://doi.org/10.1124/jpet.119.264226 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 374:113–125, July 2020 Copyright ª 2020 by The American Society for Pharmacology and Experimental Therapeutics This is an open access article distributed under the CC BY Attribution 4.0 International license. Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl- phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease s Susanna Waters, Clas Sonesson, Peder Svensson, Joakim Tedroff, Manolo Carta, Elisabeth Ljung, Jenny Gunnergren, Malin Edling, Boel Svanberg, Anne Fagerberg, Johan Kullingsjö, Stephan Hjorth, and Nicholas Waters Integrative Research Laboratories Sweden AB, Göteborg, Sweden (S.W., C.S., P.S., J.T., E.L., J.G., M.E., B.S., A.F., J.K., N.W.); Pharmacilitator AB, Vallda, Sweden (S.H.); Department of Molecular and Clinical Medicine, Institute of Medicine, The Downloaded from Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden (S.H.); Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy (M.C.); Department of Pharmacology, Gothenburg University, Gothenburg, Sweden (S.W.); and Department of Clin Neuroscience, Karolinska Institute, Stockholm, Sweden (J.T.) Received December 18, 2019; accepted April 2, 2020 jpet.aspetjournals.org ABSTRACT IRL790 ([2-(3-fluoro-5-methanesulfonylphenoxy)ethyl](propyl)amine, early gene (IEG) response profiles suggest modulation of DA mesdopetam) is a novel compound in development for the neurotransmission, with some features, such as increased DA clinical management of motor and psychiatric disabilities in metabolites and extracellular DA, shared by atypical antipsy- Parkinson disease.
    [Show full text]
  • AHRQ Healthcare Horizon Scanning System – Status Update Horizon
    AHRQ Healthcare Horizon Scanning System – Status Update Horizon Scanning Status Update: July 2014 Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. HHSA290201000006C Prepared by: ECRI Institute 5200 Butler Pike Plymouth Meeting, PA 19462 July 2014 Statement of Funding and Purpose This report incorporates data collected during implementation of the Agency for Healthcare Research and Quality (AHRQ) Healthcare Horizon Scanning System by ECRI Institute under contract to AHRQ, Rockville, MD (Contract No. HHSA290201000006C). The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. A novel intervention may not appear in this report simply because the System has not yet detected it. The list of novel interventions in the Horizon Scanning Status Update Report will change over time as new information is collected. This should not be construed as either endorsements or rejections of specific interventions. As topics are entered into the System, individual target technology reports are developed for those that appear to be closer to diffusion into practice in the United States. A representative from AHRQ served as a Contracting Officer’s Technical Representative and provided input during the implementation of the horizon scanning system. AHRQ did not directly participate in the horizon scanning, assessing the leads or topics, or provide opinions regarding potential impact of interventions.
    [Show full text]
  • WHO Drug Information Vol
    WHO Drug Information Vol. 23, No. 4, 2009 World Health Organization WHO Drug Information Contents International Nonproprietary Prequalification of Medicines Names Programme INN identifiers for biological products 273 Prequalification of quality control laboratories 300 Safety and Efficacy Issues Rituximab: multifocal leuko- Pharmacovigilance Focus encephalopathy 282 A/H1N1 vaccination safety: PaniFlow® Darbepoetin alfa: risk of stroke 282 surveillance tool 305 Vigabatrin and movement disorders 283 Alendronate: risk of low-energy femoral Regulatory Action and News shaft fracture 283 Influenza vaccines for 2010 southern Ceftriaxone and calcium containing hemisphere winter 306 solutions 284 Romidepsin: approved for cutaneous Etravirine: severe skin and hyper- T-cell lymphoma 306 sensitivity reactions 285 Orciprenaline sulphate: withdrawal 306 Oseltamivir phosphate: dosing risk 285 Artemisinin antimalarials: not for Safety signal: hyponatraemia 286 use as monotherapy 307 Clopidogrel and omeprazole: reduced Vitespen: withdrawal of marketing effectiveness 286 authorization application 307 Bisphosphonates: osteonecrosis of Aripiprazole: withdrawal of application the jaw 287 for extension of indication 307 Intravenous promethazine: serious Substandard and counterfeit medicines: tissue injuries 287 USAID–USP Agreement 308 Cyproterone: risk of meningiomas 288 Vandetinib: withdrawal of marketing Gadolinium-containing contrast agents 289 authorization application 308 Cesium chloride: cardiac risks 290 Washout or taper when switching antidepressants
    [Show full text]